Good afternoon. Welcome to follow Detection Technology's second quarter result announcement. My name is Hannu Martola. I am the President and CEO of Detection Technology, and I am pleased to present the results. In the second quarter, we reached sales of 25.6 million, which is a 5.1% growth year-on-year, and reached an EBITA of 1.8 million, which is slightly better than last year's 1.7 million, with an EBITA percentage of 7.1%, again slightly better than the year before. Where did it come from? So the growth continued. It was very much driven by both medical applications and TFT; the good news is that TFT growth has now started also in the Western markets. But then in total, China weighed on both our security and industrial sales. Total industrial sales were -6%. Sales of line scan products in APAC, specifically China, declined, but TFT sales grew in APAC as well as in all geographical markets for industrial and medical applications. Strong growth of 21% was driven by global CT demand. But the TFT delivers for medical. We started to deliver those security sales, which declined 8%. And this is a bit controversial because we had good growth both in Europe and the Americas in Western markets. Good growth also in APAC outside China, but the China security sales declined. The total outcome was -8%. Despite this, our global market share remains unchanged. We are a little bit stronger in the Western markets. And then in China, markets are a little bit different, as some of our customers are making products for themselves by using two sources: us and in-house. Net sales by quarter. We see here the past three or four years, including the first and second quarters of 2026. This year is up about 9.9% together. Also, EBITDA is slightly better than the reference period, which was 7.1%. Then, let us go into the regional business units. Americas, representing 7% of our sales, grew by a healthy 15%. That was driven largely by security. And I think this is also good news that in the Americas, we have had some decline in history and some structural changes. Now it is starting to grow. APAC, representing 72% of our sales, grew 2%. China declined, but overall, EMEIA represents 21% of growth. We saw nice growth of 15%. And EMEIA also was very much driven by security. I must note here also that we have some shift in security sales from Europe to outside China, in Asia. So that is also affecting these numbers.
Then by applications, industrial was -6% altogether, while medical grew 21% to 13 million euros. And security, which represents 20% of our sales, is down 8% altogether. Looking at the first six-month numbers, I believe. We saw 9.1% growth. EBITA was 8.2% and €4.2 million. And these are the results for the first six months. Regional business unit split. Americas saw 21% growth. APAC 6% growth. And Europe, Middle East, India, and Africa saw 18% growth. And the same six months by application. Industrial business saw growth of 6%. Medical growth of 19% and security flattish at -1.5%. Then, looking at the key results and numbers, a couple of things that I would like to highlight. I think the profitability here, 7.1%, is very much explained through the product mix. That is something that must be noted. It was quite heavy on medical, and that is affecting the numbers. We also have high fixed costs due to the ongoing construction of the factory in India. Enablers for future growth on the investment side that stick out are investments of 3.3 million. We made long-term investments into R&D capabilities and competencies, and therefore, our cash flow was negative 600,000 euros. Two reasons. One is the long-term investments. Then, the other factor is an increase in inventory. Return on assets. Net assets is still quite nice, 19.9%. I expect that for the future, we can improve that. Next, I want to go through what we have done in our strategy execution. We have four cornerstones. That is the base regarding our legacy technologies and doing everything better. Regarding our growth areas, we are focused on TFTs, added-value subsystems, and investing in new, long-term technology, all built on the foundation of a better-performing organization and team, as well as ensuring more satisfied, successful customers through easy-to-use products and services from Detection Technology.
I think this is quite interesting. This is the 65 million target, representing additional sales of 65 million to be reached by 2030. We have divided this, and this is something we also published at our Capital Markets Day a bit over a year ago. We have divided this into the areas for TFT: into the medical industrial CT line scan, into security CT line scan, and then into security cargo; TFT, by the way, represents one third of this growth. This is very important for us. So we have now launched more than 60 TFT products. We have launched the world's largest flat panel 43108 and its little brother 4386, which is even faster but slightly shorter. We have introduced new IGZO-TFT products for both EV battery, energy storage, and dental applications. We have launched AIDA for more value-added subsystem hardware. Software detector systems. X-ACE for high-speed medical CT. We launched AIDA for low-cost security and industrial applications. And then we have in our pipeline new both low-cost and high-performing CT products, both for medical and security. We launched X-Cargo, which is a very fast detector, especially for trains and cargo detection. And all these together are helping us now to reach our target of 65 million in additional revenue. We are working on developing new photon counting technology, which boosts the growth even higher later on. And then we have the enablers for doing this. We have opened a new sales and production site in India.
And by the way, it has just been granted a medical device manufacturing license in India. It is very fresh news. We started a new site in Shanghai, not only for a better environment for our R&D employees, sales, and administration there, but especially for new facilities for testing of products, providing much greater capacity. And then expanding the European origin capability, manufacturing in Oulu, which is helping us further into especially defense area in the Western world. On TFT sales, we saw a nice growth of 20% for the first half, and I believe it was 25% for the second quarter. But the notable thing here is that actually now TFT starts to be 10%, or one-tenth of our revenues. And out of this, roughly 10% to 20% is already coming from outside of China. We are now moving ahead well with our strategy, execution, and plans. We have seen growth in industrial applications. All regions for TFT deliveries for medical applications have started. And if we look at the order backlog. So regarding future orders, we have growth in all regions and it looks quite nice. And the most important foundation here is that now we have the world's best set of fast and large single-glass flat panel detectors. This is extremely important, especially for the defense and weapons industry.
And to back that up. Here are the two new flat panel products. We have X-Panel 4308 and 4386, and one of our customers, a representative from Fraunhofer IIS, which is the largest research institute in Europe, stated the following. I think Fraunhofer has some 35,000 research people. He said that this is a real game changer for industrial CT, and we are now stepping into the era of quality. Everybody knows the word drone. Stepping from missile to high-volume drone manufacturing requires quantity, throughput, and quality. And that is where this X-ray technology steps in. So defense drives the demand for fast and large-scale scanning for high throughput and quality. And this position has now been verified following these launches. So several customers have been verifying our products. Now we need to sell. We are number one in high-value industrial defense inspection, utilizing large dynamic panels. Okay. Stepping from products into reporting, this is something that we are now planning. We are now planning to move into IFRS reporting for the first time starting from the fourth quarter of this year. And this would then put us into the same framework with all our peer group. The transition date is 1st of January 2025, and we are reporting on the fourth quarter of 2026 as informed. And this is then helping especially the analysts and the financial community to really come up with comparable financial numbers. I would bet that it is more probable that our results will be a little bit improved than vice versa. But let's see when we finalize the planning work. Then, what do we see for the future? In the very short term, we see growth. We see growth for the third quarter and the fourth quarter. Probably the growth for the second half will be similar to the second quarter, with industrial and medical applications expected to grow, but security declining a little bit. So the official guidance for the third and fourth quarter is growth. The financial targets. Our mid-term financial targets remain the same: 10% net sales growth, 15% EBITA margin, and a 30% to 60% dividend payout ratio. So this is in a nutshell our performance for the second quarter, and we would be very happy to answer any questions if they may arise.
Thank you.